Based on the key indicators related to Reviva Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Reviva Pharmaceuticals Holdings may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. As of now, Reviva Pharmaceuticals' Other Assets are increasing as compared to previous years. The Reviva Pharmaceuticals' current Total Stockholder Equity is estimated to increase to about 10.4 M, while Other Current Liabilities is forecasted to increase to (855.6 K). Key indicators impacting Reviva Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Reviva Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Reviva Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Reviva Pharmaceuticals.
Net Income
(37.3 Million)
Reviva
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Cash Ratio
Price To Book Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Change In Cash
Net Borrowings
Other Cashflows From Financing Activities
Depreciation
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Non Cash Items
Issuance Of Capital Stock
Other Current Liab
Total Current Liabilities
Net Tangible Assets
Retained Earnings
Accounts Payable
Other Assets
Total Current Assets
Common Stock
Total Assets
Total Stockholder Equity
Net Debt
Cash
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Net Invested Capital
Capital Stock
Net Working Capital
Other Liab
Other Current Assets
Interest Expense
Ebit
Net Income Applicable To Common Shares
Income Tax Expense
Tax Provision
Net Interest Income
Interest Income
Depreciation And Amortization
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Probability Of Bankruptcy
Understanding current and past Reviva Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Reviva Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Reviva Pharmaceuticals' assets may result in an increase in income on the income statement.
Reviva Pharmaceuticals competes with Protalix Biotherapeutics, Eyepoint Pharmaceuticals, Sellas Life, In8bio, and Cue Biopharma. Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. Reviva Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Reviva Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Reviva Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Reviva Pharmaceuticals competition to find correlations between indicators driving Reviva Pharmaceuticals's intrinsic value. More Info.
Reviva Pharmaceuticals Holdings is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . As of now, Reviva Pharmaceuticals' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Reviva Pharmaceuticals' earnings, one of the primary drivers of an investment's value.
Reviva Pharmaceuticals Systematic Risk
Reviva Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Reviva Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Reviva Pharmaceuticals correlated with the market. If Beta is less than 0 Reviva Pharmaceuticals generally moves in the opposite direction as compared to the market. If Reviva Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Reviva Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Reviva Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Reviva Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Reviva Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Reviva Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Reviva Pharmaceuticals growth as a starting point in their analysis.
Reviva Pharmaceuticals November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Reviva Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Reviva Pharmaceuticals Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Reviva Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Reviva Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.